Loading
Cancer Related Cognitive Impairment Studies / Dementia and Cognitive Impairment Research · Journal article
JAMA Network Open · August 25, 2026
Well-designed and adequately powered for the question it asks.
In a large prospective cohort of older women followed up to 18 years, earlier menopause age was associated with faster global and episodic memory cognitive decline, earlier Alzheimer disease diagnosis, and—specifically in spontaneous menopause—substantially faster white matter hyperintensity accumulation. These associations persisted and intensified decades after menopause, suggesting menopause timing is a midlife marker of later neurological risk.
Prospective longitudinal cohort study. Older women from Religious Orders Study and Rush Memory and Aging Project; mean enrollment age 78.3 (SD 7.85) years; 92.2% White non-Hispanic, 6.6% Black or African American.. Intervention: Age at menopause (continuous exposure). Compared with: Earlier versus later menopause age; spontaneous versus surgical menopause type. n = 2,603. Religious Orders Study and Rush Memory and Aging Project (US-based cohorts, specific centers not enumerated in abstract).
Earlier menopause age associated with faster global cognitive decline (β = -0.0009 SD per year earlier menopause; FDR-corrected P = 0.04) Earlier menopause associated with faster episodic memory decline (β = -0.0014; FDR-corrected P = 0.03) Earlier menopause associated with earlier AD diagnosis in full cohort (time ratio = 0.998; 95% CI, 0.997–0.999; FDR-corrected P = 0.02)
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Menopause age emerges as a measurable midlife risk factor for later cognitive decline and Alzheimer disease in older women. Clinicians may consider earlier menopause as a signal for cognitive screening and preventive strategies, though the observational nature means causality is not established and individual risk prediction remains uncertain.
Large, well-designed longitudinal cohort study with up to 18 years of follow-up, prespecified statistical correction, and consistent associations across cognitive and neuroimaging endpoints, though observational design and potential confounding limit practice-changing claims.
As stated by the source record.
Quoted from the source exactly as published.
Menopause age emerges as a measurable midlife risk factor for later cognitive decline and Alzheimer disease in older women. Clinicians may consider earlier menopause as a signal for cognitive screening and preventive strategies, though the observational nature means causality is not established and individual risk prediction remains uncertain.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Importance: Earlier menopause has been linked to increased cognitive decline, but longitudinal data regarding corresponding volumetric brain changes are scarce, and the lasting associations of menopause timing on brain atrophy rates that accompany cognitive decline in women remain unknown. Objective: To evaluate whether menopause age is associated with cognitive decline, Alzheimer disease (AD) onset, and brain volume trajectories in older women and whether this differs by menopause type. Design, Setting, and Participants: Longitudinal cohort study using the Religious Orders Study and Rush Memory and Aging Project with up to 18 years of follow-up. Religious Orders Study enrollment began January 1994 and Rush Memory and Aging Project enrollment ran September 1997 to April 2005; follow-up is ongoing in both. Data were extracted and analyzed in August 2025. Analyses included 2603 women with cognitive data, 1287 with neuropathology at autopsy, and 774 with serial 3T magnetic resonance imaging. Exposures: Age at menopause, examined overall and stratified by menopause type (spontaneous vs surgical). Main Outcomes and Measures: Global and domain-specific cognitive decline, time to AD diagnosis, AD neuropathologic change at autopsy, and brain volume trajectories including total brain volume and white matter hyperintensity volume, modeled using linear mixed-effects, accelerated failure time, proportional odds, and inverse-probability-weighted generalized additive mixed models with a prespecified 3-family Benjamini-Hochberg correction. Results: From a total of 2603 women (mean [SD] age of enrollment, [78.30 [7.85],; 172 [6.6%] Black or African American and 2400 [92.2%] White non-Hispanic), earlier menopause age was associated with faster global cognitive decline (β = -0.0009 SD per year earlier menopause age; SE = 0.0004; false-discovery rate [FDR]-corrected P =.04), faster episodic memory decline (β = -0.0014; SE = 0.0005; FDR-corrected P =.03), and earlier AD diagnosis in the full cohort (time ratio = 0.998; 95% CI, 0.997-0.999; FDR-corrected P =.02); associations were directionally stronger in surgical menopause (time ratio = 1.000; 95% CI, 0.998-1.000; P =.008). Earlier menopause age was associated with substantially faster white matter hyperintensity volume accumulation in women with spontaneous menopause (f2 = 0.30; FDR-corrected P <.001), an association that increased with advancing age and was absent in surgical menopause, indicating specificity to the gradual hormonal trajectory of spontaneous menopause. Conclusions and Relevance: In this cohort study of older women, earlier menopause was associated with less favorable functional and structural neurological outcomes, with associations persisting and intensifying decades after the menopausal transition. These findings position menopause age as a midlife-identifiable marker for risk stratification, offering a window for targeted prevention before structural or cognitive changes become apparent.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.